Want to see ESLOY full AI Analyst Report?
ESLOY Stock Chart & Stats
$93.02
$0.66(0.72%)
At close: 4:00 PM EDT
$93.02
$0.66(0.72%)
Day’s Range― - ―
52-Week Range$92.05 - $186.18
Previous CloseN/A
Volume121.34K
Average Volume (3M)2.59K
Market Cap
$87.60B
Enterprise Value$103.22K
Total Cash (Recent Filing)$1.93B
Total Debt (Recent Filing)$15.31B
Price to Earnings (P/E)30.4
Beta0.86
Next Earnings
Feb 17, 2027EPS Estimate
1.99Next Dividend Ex-DateN/A
Dividend Yield2.45%
Share Statistics
EPS (TTM)2.73
Shares Outstanding928,495,100
10 Day Avg. Volume2,986
30 Day Avg. Volume2,591
Financial Highlights & Ratios
PEG Ratio-8.26
Price to Book (P/B)3.18
Price to Sales (P/S)4.34
P/FCF Ratio34.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.2
Revenue Forecast (FY)$34.58B
Bulls Say, Bears Say
Bulls Say
Vertical Integration & DistributionOwning design, manufacturing and retail creates durable margin capture and supply‑chain control. This reduces dependence on third parties, speeds product rollouts, and lets the company optimize channel mix (wholesale vs DTC), supporting stable revenue and margin resilience over the next 2–6 months.
Product Innovation & Strategic PartnershipsPartnerships and in‑house wearables manufacturing scale a structural move into smart optics and medtech. This builds a sustainable competitive edge: proprietary tech, faster industrialization, and new high‑margin adjacencies (wearables, intelligent systems) that can drive multi‑period revenue and margin improvement.
Strong Cash Generation & ProfitabilityConsistent, elevated free cash flow and solid gross margins (~61%) provide durable financial flexibility to fund R&D, capex for wearables/medtech, and retail investments. Reliable cash conversion supports strategic initiatives and buffers cyclical softness, strengthening long‑term execution capacity.
Bears Say
Rising LeverageA meaningful increase in leverage reduces financial flexibility and raises interest expense sensitivity. Higher debt levels constrain optionality for M&A, buybacks or cyclical buffering, increasing vulnerability to rate moves and potentially pressuring net income and free cash flow in coming quarters.
Concentration Of Myopia GrowthHeavy dependence on one geography for a key growth engine raises execution and macro risk. Any Chinese policy, reimbursement, or consumer slowdown would disproportionately affect myopia momentum and hurt global rollout pacing, making near‑term growth projections more contingent and less diversified.
FX, Tariffs And H2 Comparison UncertaintyTiming of tariff refunds/payments and currency swings create structural modeling uncertainty for revenue and margins. A difficult H2 comp amplifies this, complicating predictability of reported growth and free cash flow sequencing, and may force cautious investment or promotional decisions.
EssilorLuxottica SA News
ESLOY FAQ
What was EssilorLuxottica SA’s price range in the past 12 months?
EssilorLuxottica SA lowest stock price was $92.05 and its highest was $186.18 in the past 12 months.
What is EssilorLuxottica SA’s market cap?
EssilorLuxottica SA’s market cap is $87.60B.
When is EssilorLuxottica SA’s upcoming earnings report date?
EssilorLuxottica SA’s upcoming earnings report date is Feb 17, 2027 which is in 191 days.
How were EssilorLuxottica SA’s earnings last quarter?
EssilorLuxottica SA released its earnings results on Jul 28, 2026. The company reported $1.918 earnings per share for the quarter, missing the consensus estimate of $2.22 by -$0.302.
Is EssilorLuxottica SA overvalued?
According to Wall Street analysts EssilorLuxottica SA’s price is currently Overvalued.
Does EssilorLuxottica SA pay dividends?
EssilorLuxottica SA pays a Annually dividend of $2.317 which represents an annual dividend yield of 2.45%. See more information on EssilorLuxottica SA dividends here
What is EssilorLuxottica SA’s EPS estimate?
EssilorLuxottica SA’s EPS estimate is 1.99.
How many shares outstanding does EssilorLuxottica SA have?
EssilorLuxottica SA has 928,495,100 shares outstanding.
What happened to EssilorLuxottica SA’s price movement after its last earnings report?
EssilorLuxottica SA reported an EPS of $1.918 in its last earnings report, missing expectations of $2.22. Following the earnings report the stock price went up 2.095%.
Which hedge fund is a major shareholder of EssilorLuxottica SA?
Currently, no hedge funds are holding shares in ESLOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EssilorLuxottica SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ESLOY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 50.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.83%
12-Months-Change
Fundamentals
Return on Equity
2.45%
Trailing 12-Months
Asset Growth
2.32%
Trailing 12-Months
Company Description
EssilorLuxottica SA
EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. The company specializes in the creation, production, and worldwide distribution of a diverse range of vision products, including ophthalmic lenses, eyewear frames, and sunglasses, catering to markets across North America, Europe, Latin America, Asia, Oceania, and Africa. Its extensive operations are divided into five key segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division is responsible for manufacturing and supplying premium and athletic eyewear to other businesses. Conversely, the Retail segment directly offers luxury and sports eyewear to consumers through its various sales channels. The Lenses and Optical Instruments segment provides a broad spectrum of lenses, such as Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (including the Gen 8 series), Eyezen lenses optimized for digital screen use, and Xperio polarized sun lenses, alongside corrective options from Nikon and Kodak. This segment also furnishes optical instruments, including lens edging and mounting equipment for opticians and laboratories, and optometry tools for a variety of professionals and institutions, while also developing online optical sales solutions. The Equipment segment focuses on delivering advanced digital surfacing and lens coating machinery to prescription laboratories, integrated optical chains, and lens manufacturers. Lastly, the Sunglasses and Readers segment encompasses a wide array of non-prescription sunglasses and reading glasses, available under numerous well-known proprietary brands like Foster Grant, Magnivision, and SolarShield, licensed brands such as Reebok, Steve Madden, and Disney, and regional labels including Bolon and Mujosh. To support its expansive business, EssilorLuxottica maintains a substantial network of 490 prescription laboratories and edging-mounting facilities globally. The company formally adopted the name EssilorLuxottica Société anonyme in October 2018, having previously been known as Essilor International Société Anonyme.
ESLOY Company Deck
ESLOY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive operational and financial picture: solid double-digit-like improvements in profitability metrics, strong free cash flow, robust regional momentum (notably Asia Pacific), and clear product and strategic progress in wearables, myopia management and medtech. Management acknowledged localized slowdowns (key accounts in North America, flat France, some EMEA licensing softness), currency and tariff timing uncertainties, and a demanding H2 comparison base. Overall the positives (revenue growth, margin recovery, record cash generation, product pipeline and strategic partnerships) materially outweigh the noted operational and timing risks.View all ESLOY earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Cooper Co
―
Staar Surgical
―
Precision Optics Corporation
―
Bausch + Lomb Corporation
―
Innovative Eyewear, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors










